| Document |
Document Title |
|
WO/2017/023912A1 |
Compounds according to Formula (I) are provided and salts thereof, wherein R1, R2, R 3 , R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Formula (I) are also provided, as well as methods of treating ...
|
|
WO/2017/017505A1 |
Invention is related to novel compounds – benzenesulfonamides of general formulas (I) and (II). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...
|
|
WO/2017/013375A1 |
The invention relates to a process for preparing ionomers of unipolar cationic conductivity from fluorine-containing ionic monomers, to said ionomers of unipolar cationic conductivity, to their uses, to an electrolytic composition compri...
|
|
WO/2017/013265A1 |
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...
|
|
WO/2017/011323A1 |
Compounds that inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.
|
|
WO/2017/006929A1 |
The present invention makes it easy to obtain, with good yield and stereoselectivity, an optically active α-tetrasubstituted α-amino nitrile derivative, or an intermediate for the synthesis of said derivative, by reacting a cyanometala...
|
|
WO/2016/203314A1 |
The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents...
|
|
WO/2016/205203A1 |
The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of bel...
|
|
WO/2016/199906A1 |
The purpose of the present invention is to provide a novel low-molecular-weight compound which exhibits orexin receptor agonist activity and is expected to be useful as a prophylactic agent or therapeutic agent for narcolepsy and the lik...
|
|
WO/2016/198507A1 |
Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing C6 heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected fro...
|
|
WO/2016/198374A1 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2016/193452A1 |
The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.
|
|
WO/2016/193470A1 |
The present invention relates to compounds according to Formula (I): or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.
|
|
WO/2016/183534A1 |
The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosi...
|
|
WO/2016/177765A1 |
The invention relates to a method for the preparation of bis(fluorosulfonyl)-imide and its derivatives at elevated temperature.
|
|
WO/2016/172425A1 |
Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)
|
|
WO/2016/168059A1 |
This disclosure relates to the field of moiecuies having pesticida i utility against pests in Phyla Arthropoda, Moliusca, and hJematoda, processes to produce such moiecuies, intermediates used In such processes, pesticidai compositions c...
|
|
WO/2016/168058A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2016/167361A1 |
The purpose of the present invention is to provide a novel method for producing an organic compound substantially free of Pd in an inexpensive and simple manner. The present invention pertains to a method for producing an organic compoun...
|
|
WO/2016/162299A1 |
The invention relates to a method for producing compounds of formula (Ia), in particular to a method for producing N-[4-(cyclopropylcarbamoyl)phenylsulfonyl]-2-methoxybenzamid
e.
|
|
WO/2016/158842A1 |
The present invention provides a heat-resistant aliphatic-chain saturated hydrocarbon having ion pairs at both ends and a thermally conductive composition or the like containing the same. In the present invention, ion pairs are introduce...
|
|
WO/2016/153242A1 |
The present invention relates to an amide derivative compound or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a pharmaceutical composition for treating or preventing central nervous system disease, t...
|
|
WO/2016/143637A1 |
[Problem] The present invention addresses the problem of providing a new method that is for manufacturing a primary amine through catalytic hydrogen reduction of a nitrile and that enables obtaining of a primary amine with high selectivi...
|
|
WO/2016/144087A1 |
The present invention relates to an N-phenyl-N'-phenoxycarbonyl-phenylsulfonhydrazide derivative which has excellent activity in inhibiting PGE2 production, a method for preparing the same, and a pharmaceutical composition comprising the...
|
|
WO/2016/141301A1 |
Embodiments of the present disclosure pertain to compositions that include a boron nitride, an ionic liquid, and a lithium salt. Such compositions may be in the form of a composite and utilized as an electrolyte, a separator, or an elect...
|
|
WO/2016/136203A1 |
The present invention is a crystalline modification which is a novel crystalline form of N-(2-(3-phenylureido)phenyl)benzenesulfonamide, and is characterized by an X-ray diffraction pattern, obtained by powder X-ray diffractometry using ...
|
|
WO/2016/133317A1 |
The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxi...
|
|
WO/2016/131098A1 |
ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in ...
|
|
WO/2016/133160A1 |
The purpose of the present invention is to provide a novel low molecular weight compound that exhibits orexin receptor agonist activity and is expected to be useful as an excellent preventative or therapeutic agent for narcolepsy or the ...
|
|
WO/2016/129983A1 |
The present invention relates to novel N-acyl-diarysulfonamides acting as inhibitors of bacterial aminoacyl-tRNA synthetase. These can be used as medicines or as constituent of medicines for the treatment of bacterial infections.
|
|
WO/2016/125845A1 |
An aromatic compound and a sulfonimide compound can be cross-coupled safely and easily using a wide variety of substrates by reacting an aromatic compound and a specific sulfonimide compound in the presence of a copper compound and a spe...
|
|
WO/2016/127085A1 |
Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such ...
|
|
WO/2016/122195A1 |
The present specification relates to a compound comprising an aromatic ring, a polymer comprising same, a polyelectrolyte membrane comprising same, a membrane-electrode assembly comprising the polyelectrolyte membrane, a fuel cell compri...
|
|
WO/2016/122200A1 |
The present specification relates to a compound comprising an aromatic ring, a polyelectrolyte membrane comprising same, a membrane-electrode assembly comprising the polyelectrolyte membrane, a fuel cell comprising the membrane-electrode...
|
|
WO/2016/119349A1 |
Disclosed is a preparation method for a compound represented by formula (I). The compound represented by formula (I) is prepared by reacting a compound represented by formula (II) with a compound represented by formula (III) under the ca...
|
|
WO/2016/121439A1 |
A lubricant which comprises an ionic liquid that includes a conjugate base and a conjugate acid that has two or more cations in a molecule, the conjugate acid having a monovalent group that includes a linear hydrocarbon group having six ...
|
|
WO/2016/112386A1 |
The presently disclosed subject matter provides methods for quantifying levels of glutamine antagonists, such as 6-diazo-5-oxo-L-norleucine (DON), including such glutamine antagonists resulting from in vivo conversion of ester prodrugs o...
|
|
WO/2016/111658A1 |
The present invention relates to the synthesis method of thiosemicarbazone derivatives comprising sulphonamide group and having high anticonvulsant/antiepileptic activity.
|
|
WO/2016/112177A1 |
The invention includes a method of preventing or treating a DNA repair protein-deficient cancer in a subject in need thereof. In certain embodiments, the protein comprises BRCA2. In other embodiments, the protein comprises PTEN.
|
|
WO/2016/101885A1 |
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The ...
|
|
WO/2016/097001A1 |
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4- methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-met...
|
|
WO/2016/096720A1 |
A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.
|
|
WO/2016/099995A1 |
An ionic diol has formula wherein R1 represents an alkyl group having from 6 to 18 carbon atoms; R2 and R3 independently represent alkyl groups having from 1 to 4 carbon atoms; R4 represents an alkylene group having from 2 to 8 carbon at...
|
|
WO/2016/097389A1 |
The invention relates to benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan rece...
|
|
WO/2016/093399A1 |
The present invention is directed to a lithium sulfonyl imide salt containing fluorine and its purification method and, more particularly to, a lithium sulfonyl imide salt containing fluorine and its purification method that includes rec...
|
|
WO/2016/091772A1 |
The invention relates to a method for producing an oxysulphidic and fluorinated derivative in the form of a salt of formula (II) Ea-SOO-Q+ (II) comprising providing an ionic liquid compound of formula (I) in the liquid state Ea-SOO-Q+ (I...
|
|
WO/2016/094897A1 |
Described herein are methods and compositions relating to the treatment of e.g., cancer, autoimmune disease, immune deficiency, and/or neurodegenerative disease. In some embodiments, the methods of treatment relate to administering a com...
|
|
WO/2016/088082A1 |
The present invention provides a compound of formula (I): (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents an...
|
|
WO/2016/086762A1 |
The present invention belongs to the field of chemical synthesis, and in particular relates to a benzylsulfamide substituted acrylamide derivative. The advantages of the present invention lie in: (1) a traditional preparation route is ad...
|
|
WO/2016/085391A1 |
The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for ...
|
